AI and Cloud Computing Helping in the Development of a COVID-19 Vaccine - COVID-19 Clinical Trial
Breaking News | COVID-19

AI and Cloud Computing Helping in the Development of a COVID-19 Vaccine

A potential COVID-19 vaccine has been developed by researchers using AI and cloud computing to prevent the Spike protein from binding to the ACE2 receptor on human cells. The researchers used computer models of the S protein and its human receptor, angiotensin converting enzyme 2 (ACE2), to identify how the virus was infecting human cells. They were then able to design a vaccine to block this process. 


Why It’ll Still Take More Than a Year to Develop a Vaccine 

Despite positive reports from initial clinical trials, experts tell Healthline the best-case scenario for a vaccination delivered to market is probably 18 months to 2 years. That may sound like too long, given the seriousness of the COVID-19 pandemic, but it’s quicker than the 5 to 10 years for many vaccines. Scientists all around the world are working together in order to find a cure, but even if a cure is found, disribution will be the next challenge.  


J&J HIV Drug Prezista Fails in Vitro Study 

Scientists conducting an in vitro study at Johnson & Johnson found that an HIV drug, Prezista, already in clinical development for Covid-19 failed to show activity against the virus that causes it, SARS-CoV-2. Still, numerous other drugs are in development as potential therapies for Covid-19. Remdesivir, the Gilead drug against which Prezista was tested at J&J, is in two Phase III clinical trials run by the company itself, while a Chinese study is expected to report data this month. Regeneron Pharmaceuticals and Sanofi are testing Kevzara (sarilumab), while Moderna is testing a vaccine, mRNA-1273. 

Share this:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on reddit
Reddit
Share on email
Email
Scroll to Top

Your choice regarding cookies on this site

We use cookies to optimize site functionality and give you the best experience. Necessary cookies enable core functionality. The website cannot function properly without these cookies and can only be disabled by changing your browser preferences.

For more detailed information on the cookies we use, please check our Privacy Policy.

By continuing to access this website you are giving us consent to collect cookies.

Want to stay informed?

With an ever-changing situation like COVID-19, it’s important to stay as tuned in as possible. Submit your information below so we can send you periodic updates.